Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Compass Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$0.11 | -$0.10 | -$0.11 |
| Q2 2025 | 6 | -$0.14 | -$0.10 | -$0.12 |
| Q3 2025 | 3 | -$0.13 | -$0.13 | -$0.13 |
| Q4 2025 | 3 | -$0.13 | -$0.13 | -$0.13 |
| Q1 2026 | 4 | -$0.12 | -$0.12 | -$0.12 |
| Q2 2026 | 3 | -$0.12 | -$0.12 | -$0.12 |
| Q3 2026 | 3 | -$0.11 | -$0.11 | -$0.11 |
| Q4 2026 | 4 | -$0.09 | -$0.09 | -$0.09 |
| Q1 2027 | 2 | -$0.04 | -$0.04 | -$0.04 |
| Q2 2027 | 2 | -$0.03 | -$0.03 | -$0.03 |
| Q3 2027 | 2 | -$0.04 | -$0.04 | -$0.04 |
| Q4 2027 | 2 | -$0.05 | -$0.05 | -$0.05 |
| Q1 2028 | 3 | $0.12 | $0.12 | $0.12 |
| Q2 2028 | 3 | $0.14 | $0.14 | $0.14 |
| Q3 2028 | 3 | $0.13 | $0.13 | $0.13 |
| Q4 2028 | 3 | $0.12 | $0.12 | $0.12 |
Compass Therapeutics, Inc. Earnings Date And Information
Compass Therapeutics, Inc. last posted its earnings results on Thursday, May 8th, 2025. The company reported $-0.12 earnings per share for the quarter, missing analysts' consensus estimates of $-0.12 by $0. The company had revenue of 0 for the quarter and had revenue of 850.00 K for the year. Compass Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.36 diluted earnings per share) and currently has a price-to-earnings ratio of -6.41. Compass Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 11th, 2025 based on prior year's report dates.
Compass Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/08/2025 | Q1 2025 | -$0.12 | -$0.12 | 0 | $0 | $0 |
| 02/27/2025 | Q4 2024 | -$0.10 | -$0.11 | -0.01 | N/A | $0 |
| 09/30/2024 | Q3 2024 | N/A | -$0.08 | N/A | $0 | $0 |
| 08/12/2024 | Q2 2024 | -$0.10 | -$0.10 | 0.01 | $0 | $850.00 K |
| 05/13/2024 | Q1 2024 | -$0.11 | -$0.08 | 0.03 | $0 | $0 |
| 03/21/2024 | Q4 2023 | -$0.09 | -$0.11 | -0.02 | N/A | $2.84 M |
| 11/09/2023 | Q3 2023 | -$0.11 | -$0.08 | 0.03 | N/A | $0 |
| 08/03/2023 | Q2 2023 | -$0.08 | -$0.09 | -0.01 | N/A | $0 |
| 05/04/2023 | Q1 2023 | -$0.11 | -$0.05 | 0.06 | N/A | $0 |
| 03/15/2023 | Q4 2022 | -$0.11 | -$0.10 | 0.01 | N/A | $0 |
| 11/09/2022 | Q3 2022 | -$0.11 | -$0.11 | 0 | N/A | $0 |
| 08/01/2022 | Q2 2022 | -$0.09 | -$0.08 | 0.01 | N/A | $0 |
| 05/09/2022 | Q1 2022 | -$0.14 | -$0.07 | 0.07 | N/A | $0 |
| 03/18/2022 | Q4 2021 | N/A | -$0.25 | N/A | N/A | $0 |
| 11/12/2021 | Q3 2021 | -$0.12 | -$0.10 | 0.02 | N/A | $0 |
| 08/16/2021 | Q2 2021 | N/A | -$1.07 | N/A | N/A | $0 |
| 04/30/2021 | Q1 2021 | N/A | -$0.14 | N/A | N/A | $0 |
| 03/05/2021 | Q4 2020 | N/A | -$0.14 | N/A | N/A | $0 |
| 11/09/2020 | Q3 2020 | N/A | -$0.15 | N/A | N/A | $0 |
| 08/13/2020 | Q2 2020 | N/A | -$0.11 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Compass Therapeutics, Inc. Earnings: FAQ's
Compass Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 11th, 2025 based offlast year's report dates.
The conference call for Compass Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Compass Therapeutics, Inc.'s latest earnings report can be read online.
Compass Therapeutics, Inc. (:CMPX) has a recorded annual revenue of $850.00 K.
Compass Therapeutics, Inc. (:CMPX) has a recorded net income of $-49,375,000.Compass Therapeutics, Inc. has generated $-0.36 earnings per share over the last four quarters.
Compass Therapeutics, Inc. (:CMPX) has a price-to-earnings ratio of -6.41 and price/earnings-to-growth ratio is 0.58.